Posted by Michael Wonder on 31 Oct 2023
Schedule of Pharmaceutical Benefits - 1 November 2023
1 November 2023 - The November 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The November issue of the Schedule includes a few major new/revised listings:
- Budesonide (Jorveza) - restriction change
- Glycomacropeptide with essential amino acids and vitamins and minerals (Camino Pro Bettermilk) - new formulation
- Empagliflozin (Jardiance) - new indication
- Enoxaparin sodium (Exarane Forte) - new biosimilar medicine
- Fremanezumab (Ajovy) - new indication
- Ravulizumab (Ultomiris) - new indication
- Trastuzumab deruxtecan (Enhertu) - new medicine
- Ursodeoxycholic acid (Ursofalk) - restriction change
